BidaskClub upgraded shares of Myriad Genetics (NASDAQ:MYGN) from a sell rating to a hold rating in a report issued on Thursday.
A number of other equities analysts have also recently commented on the company. TheStreet cut Myriad Genetics from a b rating to a c rating in a report on Thursday, November 8th. ValuEngine cut Myriad Genetics from a buy rating to a hold rating in a report on Thursday, November 8th. Deutsche Bank boosted their price objective on Myriad Genetics from $37.00 to $43.00 and gave the stock a hold rating in a report on Monday, November 5th. Zacks Investment Research cut Myriad Genetics from a buy rating to a hold rating in a report on Monday, October 29th. Finally, Morgan Stanley boosted their price objective on Myriad Genetics from $51.00 to $54.00 and gave the stock an overweight rating in a report on Wednesday, October 10th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company. Myriad Genetics currently has an average rating of Hold and a consensus price target of $41.90.
Myriad Genetics stock opened at $30.71 on Thursday. Myriad Genetics has a 52 week low of $27.27 and a 52 week high of $50.44. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.17 and a quick ratio of 2.83. The stock has a market cap of $2.30 billion, a P/E ratio of 25.59, a price-to-earnings-growth ratio of 1.78 and a beta of 0.51.
Several large investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Myriad Genetics by 4.4% during the third quarter. Vanguard Group Inc. now owns 8,656,933 shares of the company’s stock worth $398,219,000 after acquiring an additional 365,697 shares during the period. Morgan Stanley boosted its holdings in shares of Myriad Genetics by 110.9% during the third quarter. Morgan Stanley now owns 737,327 shares of the company’s stock worth $33,916,000 after acquiring an additional 387,692 shares during the period. Legal & General Group Plc boosted its holdings in shares of Myriad Genetics by 10.8% during the third quarter. Legal & General Group Plc now owns 165,855 shares of the company’s stock worth $7,646,000 after acquiring an additional 16,186 shares during the period. Kepos Capital LP acquired a new stake in shares of Myriad Genetics in the third quarter valued at approximately $3,545,000. Finally, Nordea Investment Management AB raised its position in shares of Myriad Genetics by 23.7% in the third quarter. Nordea Investment Management AB now owns 101,483 shares of the company’s stock valued at $4,669,000 after buying an additional 19,417 shares in the last quarter. Institutional investors own 98.21% of the company’s stock.
Myriad Genetics Company Profile
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Featured Story: Why is Cost of Capital Important?
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.